文献速递淋巴瘤造血干细胞移植与细胞治疗

抗生素诱导的肠道微生物组代谢输出丢失与CAR-T细胞治疗临床反应相关

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.
PubMed 文献 · Blood · 2025-01-01

本研究在422例大B细胞淋巴瘤患者中观察到,既往暴露于哌拉西林-他唑巴坦和美罗培南等广谱抗生素与抗CD19 CAR-T治疗生存结局较差相关。在发现集67例和外部验证集58例中,这些抗生素与肠道微生物组功能失调及肠血代谢组改变相关,并在小鼠模型中重现,短链脂肪酸可增强CAR-T代谢适应性和杀伤能力。

要点

  • 既往使用哌拉西林-他唑巴坦或美罗培南等广谱抗生素与抗CD19 CAR-T治疗生存结局较差相关(N=422)。
  • 这些抗生素与肠道微生物组功能显著失调及肠血代谢组改变相关,包括短链脂肪酸等微生物效应物减少。
  • 小鼠模型中美罗培南诱导的菌群失调导致全身代谢组改变并降低抗CD19 CAR-T疗效。

核心结论

  • 广谱抗生素消耗代谢活跃的共生菌,其代谢物对增强CAR-T疗效至关重要,提示调节微生物组可能增强CAR-T免疫治疗。

研究设计与样本

  • 研究纳入422例接受抗CD19 CAR-T治疗的大B细胞淋巴瘤患者,发现集67例,外部验证集58例,另用免疫健全CAR-T小鼠模型。
  • 临床试验注册号NCT06218602。

主要发现

  • 既往暴露于哌拉西林-他唑巴坦和美罗培南等广谱抗生素与抗CD19 CAR-T治疗生存结局较差相关(N=422)。
  • 发现集67例中这些抗生素与肠道微生物组功能显著失调相关,肠血代谢组改变,外部验证集58例 largely 重现。
  • 接受抗生素治疗患者循环微生物代谢物中吲哚和甲酚衍生物及氧化三甲胺减少(发现集40例,验证集28例)。
  • 小鼠模型中美罗培南诱导的菌群失调导致全身代谢组改变并降低抗CD19 CAR-T疗效。
  • 短链脂肪酸可增强CAR-T代谢适应性,提高肿瘤杀伤能力。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antibiotic (ABX)-induced microbiome dysbiosis is widespread in oncology, adversely affecting outcomes and side effects of various cancer treatments, including immune checkpoint inhibitors and chimeric antigen receptor T-cell (CAR-T) therapies. In this study, we observed that prior exposure to broad-spectrum ABXs with extended anaerobic coverage such as piperacillin-tazobactam and meropenem was associated with worse anti-CD19 CAR-T therapy survival outcomes in patients with large B-cell lymphoma (N = 422) than other ABX classes. In a discovery subset of these patients (n = 67), we found that the use of these ABXs was in turn associated with substantial dysbiosis of gut microbiome function, resulting in significant alterations of the gut and blood metabolome, including microbial effectors such as short-chain fatty acids (SCFAs) and other anionic metabolites, findings that were largely reproduced in an external validation cohort (n = 58). Broader evaluation of circulating microbial metabolites revealed reductions in indole and cresol derivatives, as well as trimethylamine N-oxide, in patients who received ABX treatment (discovery, n = 40; validation, n = 28). These findings were recapitulated in an immune-competent CAR-T mouse model, in which meropenem-induced dysbiosis led to a systemic dysmetabolome and decreased murine anti-CD19 CAR-T efficacy. Furthermore, we demonstrate that SCFAs can enhance the metabolic fitness of CAR-Ts, leading to improved tumor killing capacity. Together, these results suggest that broad-spectrum ABX deplete metabolically active commensals whose metabolites are essential for enhancing CAR-T efficacy, shedding light on the intricate relationship between ABX exposure, microbiome function and their impact on CAR-T efficacy. This highlights the potential for modulating the microbiome to augment CAR-T immunotherapy. This trial was registered at www.clinicaltrials.gov as #NCT06218602.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Prasad R, Rehman A, Rehman L, et al. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood. 2025. PMID: 39441941. doi:10.1182/blood.2024025366

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。